FAQ: Nutriband's AVERSA™ Abuse-Deterrent Technology Patent Expansion
Summary
Nutriband Inc. has filed a provisional patent application to strengthen protection for its AVERSA™ abuse-deterrent transdermal technology, covering improved aversive formulations and coating methods. This filing could extend patent protection by up to 20 years, enhancing the company's intellectual property portfolio for technology that prevents misuse of drugs with abuse potential while maintaining patient access.
What is the main announcement from Nutriband Inc.?
Nutriband has filed a provisional patent application with the U.S. Patent and Trademark Office to expand protection for its AVERSA™ abuse-deterrent transdermal technology, covering improved aversive formulations and coating application methods.
Why is this patent filing significant for Nutriband?
If converted to a non-provisional patent and granted, the new patent could extend AVERSA’s protection by up to 20 years from the filing date, strengthening the company’s intellectual property portfolio for its abuse-deterrent technology.
How does AVERSA™ technology work to prevent drug abuse?
AVERSA™ technology incorporates aversive agents into transdermal patches to prevent misuse of drugs with abuse potential while maintaining accessibility for patients who require them, preventing abuse, misuse, diversion, and accidental exposure.
What specific improvements does this new patent application cover?
The filing covers improved aversive formulations and coating application methods designed to enhance abuse deterrence and increase resistance to tampering with transdermal patches.
Where is AVERSA™ technology already protected?
AVERSA™ technology is already patented in 46 countries, providing international protection for Nutriband’s abuse-deterrent transdermal technology.
What is Nutriband’s lead product under development?
Nutriband’s lead product under development is an abuse-deterrent fentanyl patch incorporating the AVERSA™ abuse-deterrent technology to prevent misuse of this potent opioid medication.
How can investors stay updated on Nutriband news?
The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB, and the full press release can be viewed at https://ibn.fm/je0y2.
What types of drugs can AVERSA™ technology be used with?
AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, making it versatile for various pharmaceutical applications.
Where can I find more information about Nutriband Inc.?
The Company’s website is www.nutriband.com, though any material contained in or derived from the Company’s websites is not part of this press release according to the disclaimer provided.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 247856